Alyeska Investment Group L.P. lowered its stake in Nkarta, Inc. (NASDAQ:NKTX - Free Report) by 76.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 484,840 shares of the company's stock after selling 1,600,000 shares during the period. Alyeska Investment Group L.P. owned approximately 0.68% of Nkarta worth $1,372,000 as of its most recent filing with the SEC.
Other large investors have also recently bought and sold shares of the company. Invesco Ltd. grew its stake in shares of Nkarta by 478.4% during the first quarter. Invesco Ltd. now owns 69,396 shares of the company's stock worth $128,000 after buying an additional 57,399 shares during the last quarter. AQR Capital Management LLC boosted its stake in shares of Nkarta by 300.5% during the first quarter. AQR Capital Management LLC now owns 672,078 shares of the company's stock valued at $1,237,000 after purchasing an additional 504,272 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Nkarta by 13.3% during the first quarter. Goldman Sachs Group Inc. now owns 681,068 shares of the company's stock valued at $1,253,000 after purchasing an additional 80,211 shares in the last quarter. Jane Street Group LLC increased its position in Nkarta by 118.7% in the 1st quarter. Jane Street Group LLC now owns 134,286 shares of the company's stock valued at $247,000 after acquiring an additional 852,559 shares during the period. Finally, Geode Capital Management LLC grew its stake in shares of Nkarta by 0.8% in the second quarter. Geode Capital Management LLC now owns 1,208,378 shares of the company's stock worth $2,006,000 after purchasing an additional 10,065 shares during the last quarter. 80.54% of the stock is currently owned by institutional investors and hedge funds.
Nkarta Price Performance
Shares of Nkarta stock opened at $2.70 on Wednesday. Nkarta, Inc. has a 1 year low of $1.70 and a 1 year high of $3.72. The firm has a market cap of $193.37 million, a PE ratio of -1.72 and a beta of 0.96. The stock has a fifty day moving average price of $2.62 and a 200-day moving average price of $2.62.
Nkarta (NASDAQ:NKTX - Get Free Report) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.54) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.18). As a group, equities analysts anticipate that Nkarta, Inc. will post -1.6 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
NKTX has been the topic of a number of recent analyst reports. Evercore set a $9.00 price target on shares of Nkarta in a research report on Monday, May 18th. Weiss Ratings restated a "sell (d-)" rating on shares of Nkarta in a report on Wednesday, June 24th. HC Wainwright cut their price target on shares of Nkarta to $14.00 and set a "buy" rating on the stock in a research report on Tuesday, August 11th. Wall Street Zen downgraded Nkarta from a "sell" rating to a "strong sell" rating in a report on Saturday, August 15th. Finally, Stifel Nicolaus lowered their price objective on Nkarta from $11.00 to $10.00 and set a "buy" rating for the company in a research report on Friday, August 14th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $11.20.
View Our Latest Analysis on NKTX
About Nkarta
(
Free Report)
Nkarta, Inc is a clinical-stage biotechnology company specializing in the development of off-the-shelf natural killer (NK) cell therapies for the treatment of cancer. Leveraging proprietary activation and expansion technologies, Nkarta aims to harness the innate tumor-killing properties of NK cells while incorporating targeted immuno-engineering approaches to enhance safety, potency and persistence in patients. The company's platform supports both allogeneic cell manufacturing and genetic modifications to generate chimeric antigen receptor-expressing NK cell candidates designed to address a range of hematologic and solid tumors.
Nkarta's lead program, NKX019, is an anti-CD19 CAR-NK cell therapy in early-phase clinical trials for relapsed or refractory B-cell malignancies.
Featured Stories
Want to see what other hedge funds are holding NKTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nkarta, Inc. (NASDAQ:NKTX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Nkarta, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nkarta wasn't on the list.
While Nkarta currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
